Abstract
Antiproliferative agents include Mycophenolic acid and Azathioprine (which is less commonly used unless in certain conditions). They were initially identified for use in autoimmune and cancer research due to their role in disruption of cellular replication. They have now become the cornerstone of antirejection maintenance therapy in solid organ transplant. In this chapter we will describe the major times that lead to discovery, mechanisms of action, side effects, use during pregnancy and the major clinical trials.
| Original language | English (US) |
|---|---|
| Title of host publication | Handbook of Experimental Pharmacology |
| Publisher | Springer Science and Business Media Deutschland GmbH |
| Pages | 39-52 |
| Number of pages | 14 |
| DOIs | |
| State | Published - 2022 |
Publication series
| Name | Handbook of Experimental Pharmacology |
|---|---|
| Volume | 272 |
| ISSN (Print) | 0171-2004 |
| ISSN (Electronic) | 1865-0325 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Biochemistry
- Pharmacology, Toxicology and Pharmaceutics(all)
Fingerprint
Dive into the research topics of 'Antiproliferatives and Transplantation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver